InsidersTradesSigma
Total declarations
Companies
▲ Purchases (7 ops.)
▼ Sales (1 ops.)
Insider track record
Board DirectorDisclosed buys
7
Disclosed sells
1
T+90 hit rate
100%
T+90 mean return
+23.5%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by GANNON STEVEN, Director. Officer active across 2 companies, notably Fusion Pharmaceuticals Inc.. In total, 10 disclosures have been recorded. Split: 7 buys · 1 sell. Total volume traded: €253k. History available since 16 August 2021. The latest transaction was filed on 14 May 2025 (Levée d'options). Regulator: SEC (Form 4). All data is free.
Declarations10 total
5,144 shares@ US$12.5757.6% of flowCommon SharesSEC:0000950170-25-073746:0
56,400 sharesCommon StockSEC:0000950170-24-068906:0
1,000 shares@ US$46.4542.4% of flowCommon SharesSEC:0000950170-24-028788:0
44,400 shares@ US$2.0341.5% of flowCommon StockSEC:0001209191-22-045421:0
Ideal exit: 8 May 2023 (T+270)
2,829 shares@ US$7.98515.6% of flowCommon StockSEC:0001209191-21-053000:0
Ideal exit: 20 May 2022 (T+270)
2,829 shares@ US$7.9859.1% of flowCommon StockSEC:0001209191-21-053000
Ideal exit: 20 May 2022 (T+270)
171 shares@ US$8.051.0% of flowCommon StockSEC:0000899243-21-033814:0
Ideal exit: 15 May 2022 (T+270)
171 shares@ US$8.050.6% of flowCommon StockSEC:0000899243-21-033814
Ideal exit: 15 May 2022 (T+270)
6,000 shares@ US$8.1033.5% of flowCommon StockSEC:0000899243-21-033258:0
Ideal exit: 13 May 2022 (T+270)
6,000 shares@ US$8.1019.6% of flowCommon StockSEC:0000899243-21-033258
Ideal exit: 13 May 2022 (T+270)
10 of 10 declarations
About GANNON STEVEN
Steven Gannon is a Board Member of Fusion Pharmaceuticals Inc. He contributes to the governance and strategy of the company. Steven brings valuable expertise in the pharmaceutical sector.
